{"id":"NCT01096186","sponsor":"Impax Laboratories, LLC","briefTitle":"An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease","officialTitle":"An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2010-03-31","resultsPosted":"2016-03-03","lastUpdate":"2019-11-08"},"enrollment":617,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"IPX066 95 mg","otherNames":["CD-LD ER 95 mg"]},{"type":"DRUG","name":"IPX066 145 mg","otherNames":["CD-LD ER 145 mg"]},{"type":"DRUG","name":"IPX066 195 mg","otherNames":["CD-LD ER195 mg"]},{"type":"DRUG","name":"IPX066 245 mg","otherNames":["CD-LD ER 245 mg"]}],"arms":[{"label":"Open Label IPX066","type":"OTHER"}],"summary":"The purpose of this study is to determine the long term safety and clinical utility of IPX066 in subjects with Parkinson's Disease.","primaryOutcome":{"measure":"Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III","timeFrame":"9 months","effectByArm":[{"arm":"IPX066","deltaMin":26.4,"sd":13.3}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":81,"countries":["United States","Canada","Estonia","Germany","Latvia","Lithuania","Poland","Romania","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":617},"commonTop":["Insomnia","Dyskinesia","Fall","Nausea"]}}